AR023617A1 - Utilizacion del (2s)-1-[(2r,3s)-5-cloro-3-(2-clorofenil)-1-(3,4-dimetoxibencensulfonil)-3-hidroxi-2,3-dihidro-1h-indol-2-carbonil]pirrolidin-2-carboxamidapara la preparacion de medicamentos utiles en el tratamiento del fenomeno de raynaud - Google Patents

Utilizacion del (2s)-1-[(2r,3s)-5-cloro-3-(2-clorofenil)-1-(3,4-dimetoxibencensulfonil)-3-hidroxi-2,3-dihidro-1h-indol-2-carbonil]pirrolidin-2-carboxamidapara la preparacion de medicamentos utiles en el tratamiento del fenomeno de raynaud

Info

Publication number
AR023617A1
AR023617A1 ARP000101990A ARP000101990A AR023617A1 AR 023617 A1 AR023617 A1 AR 023617A1 AR P000101990 A ARP000101990 A AR P000101990A AR P000101990 A ARP000101990 A AR P000101990A AR 023617 A1 AR023617 A1 AR 023617A1
Authority
AR
Argentina
Prior art keywords
dihydro
preparation
treatment
dimetoxibencensulfonil
chlorophenil
Prior art date
Application number
ARP000101990A
Other languages
English (en)
Original Assignee
Addario Ezio Nicola D
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addario Ezio Nicola D filed Critical Addario Ezio Nicola D
Publication of AR023617A1 publication Critical patent/AR023617A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Utilizacion del (2S)-1-[(2R,3S)-5-cloro-3-(2-clorofenil)-1-(3,4-dimetoxibencensulfonil)-3-hidroxi-2,3-dihidro-1H-indol-2-carbonil]pirrolidin-2-carboxamida,de sus solvatos y/o hidratos farmacéuticamente aceptables, para la preparacion de medicamentosutiles en el tratamiento o la prevencion del fenomeno deRaynaud.
ARP000101990A 1999-04-29 2000-04-27 Utilizacion del (2s)-1-[(2r,3s)-5-cloro-3-(2-clorofenil)-1-(3,4-dimetoxibencensulfonil)-3-hidroxi-2,3-dihidro-1h-indol-2-carbonil]pirrolidin-2-carboxamidapara la preparacion de medicamentos utiles en el tratamiento del fenomeno de raynaud AR023617A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9905434A FR2792834A1 (fr) 1999-04-29 1999-04-29 Utilisation du sr 49059, de ses solvats et/ou hydrates pharmaceutiquement acceptables, pour la preparation de medicaments utiles dans le traitement ou la prevention du phenomene de raynaud

Publications (1)

Publication Number Publication Date
AR023617A1 true AR023617A1 (es) 2002-09-04

Family

ID=9545016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000101990A AR023617A1 (es) 1999-04-29 2000-04-27 Utilizacion del (2s)-1-[(2r,3s)-5-cloro-3-(2-clorofenil)-1-(3,4-dimetoxibencensulfonil)-3-hidroxi-2,3-dihidro-1h-indol-2-carbonil]pirrolidin-2-carboxamidapara la preparacion de medicamentos utiles en el tratamiento del fenomeno de raynaud

Country Status (4)

Country Link
AR (1) AR023617A1 (es)
AU (1) AU4303500A (es)
FR (1) FR2792834A1 (es)
WO (1) WO2000066117A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2679903B1 (fr) * 1991-08-02 1993-12-03 Elf Sanofi Derives de la n-sulfonyl indoline portant une fonction amidique, leur preparation, les compositions pharmaceutiques en contenant.
US5338755A (en) * 1990-07-31 1994-08-16 Elf Sanofi N-sulfonylindoline derivatives, their preparation and the pharmaceutical compositions in which they are present
FR2714378B1 (fr) * 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
FR2775598A1 (fr) * 1998-03-06 1999-09-10 Sanofi Sa Compositions pharmaceutiques contenant en association un antagoniste selectif des recepteurs v1a de l'arginine-vasopressine et un antagoniste selectif des recepteur v2 de l'arginine-vasopressine

Also Published As

Publication number Publication date
FR2792834A1 (fr) 2000-11-03
WO2000066117A1 (fr) 2000-11-09
AU4303500A (en) 2000-11-17

Similar Documents

Publication Publication Date Title
MXPA03007140A (es) Derivados de carbolina.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
BR0007078A (pt) Combinação de um recipiente de tecido úmido e um porta-recipiente, e, recipiente de tecido úmido
EE200300121A (et) CB1 retseptori antagonisti ja sibutramiini kombinatsioon, neid sisaldav farmatseutiline kompositsioon ja kasutamine lihavuse raviks
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
CL2004000551A1 (es) Compuestos derivados de triazol sustituidos con biarilo, sus sales, bloqueadores del canal de sodio; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento o prevencion del dolor.
AU5338401A (en) Methods and compositions for modulating alpha adrenergic receptor activity
DK1237549T3 (da) Lipoxin A4 og dets analoger til behandling af törre öjne
BR0014560B1 (pt) uso de uma composiÇço de tratamento de tecidos.
NO20004419D0 (no) Ny anvendelse
YU13301A (sh) Muskarinski agonisti i antagonisti
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
UY28007A1 (es) Tratamiento terapeutico
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
CL2004000877A1 (es) Combinacion farmaceutica que comprende 8a) melatonina y agonistas de la melatonina, y nicotina y agonistas receptores de nicotina; kit farmaceutico, y; uso en el tratamiento de insomnio, dificultades cognitivas y dificultades de memoria; kit farmaceu
HK1022649A1 (en) The use of levobupivacaine in paediatric surgery
BR0113165A (pt) Derivados de 4-pirimidinamina, composições farmacêuticas e métodos relacionados
ES2193065T3 (es) Nueva utilizacion del saredutant.
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
NO20033184L (no) Anvendelse av forbindelsen (+)-<alfa>-(2,3-dimetoksyfenyl)-1- [2-(4-fluorfenyl)etyl]-4-piperidinmetanol
AR023617A1 (es) Utilizacion del (2s)-1-[(2r,3s)-5-cloro-3-(2-clorofenil)-1-(3,4-dimetoxibencensulfonil)-3-hidroxi-2,3-dihidro-1h-indol-2-carbonil]pirrolidin-2-carboxamidapara la preparacion de medicamentos utiles en el tratamiento del fenomeno de raynaud
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE